secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protagenic Therapeutics, Inc.new (PTIX)
CIK:        0001022899
Form:       8-K
Filed at:   2026-02-24T23:59:59+00:00
Accession:  0001493152-26-007800
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 1.02, 2.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protagenic Therapeutics unwinds Phytanix Bio acquisition, pays $310k, settles litigation
--------------------------------------------------------------------------------

- Settlement and Unwind Agreement executed Feb 17, 2026; SEA dated May 15, 2025 terminated.
- PTIX returns 100% of Phytanix Bio shares; receives back all PTIX common and preferred stock issued as consideration.
- PTIX pays Phytanix Bio $300,000 at closing and $10,000 upon receipt of specified financial information.
- Litigation styled Protagenic v. Alterola Biotech et al. dismissed with prejudice.
- Mutual releases and indemnification provisions between parties; former Phytanix stockholders resign from PTIX positions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1022899/000149315226007800/0001493152-26-007800-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1022899/000149315226007800/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-007800

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer